Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
The single-tablet antiretroviral regimen includes Janssen’s darunavir plus Gilead’s cobicistat, emtricitabine and tenofovir alafenamide.
Charles Lyons, president and CEO of the Elizabeth Glaser Pediatric AIDS Foundation (EGPAF), analyzes data from a 2018 UNAIDS report.
Compared with a regimen based on Prezista, doravirine was better for blood lipids, including cholesterol and triglycerides.
PrEP is officially approved for adults and adolescents at risk for HIV who weigh at least 77 pounds.
A recent online survey found a high level of awareness of PrEP.
The combo of dolutegravir and lamivudine controlled HIV as well as a triple-drug combo of dolutegravir plus Truvada.
Congress passes legislation to increase access to unapproved therapies for life-threatening diseases.
Neither does the focus on Pharmacy Benefits Managers.
The integrase inhibitor is included in the single-tablet HIV regimens Triumeq and Juluca.
The approval is based on a small study of 15- to 17-year-olds.
The Food and Drug Administration approves antibody treatment Trogarzo for multidrug-resistant HIV.
This long-acting drug is linked to undetectable viral loads in former prisoners with substance use disorders.
The newly approved single-tablet regimen contains the integrase inhibitor bictegravir plus emtricitabine and tenofovir alafenamide.
The FDA commissioner wants drugmakers to “end the shenanigans.”
Juluca is a single-tablet regimen for HIV.
Researchers will genetically engineer participants’ CD4 cells, disabling the attachment of the virus.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.